Vanda Pharmaceuticals Files 8-K: Material Agreement Details
Ticker: VNDA · Form: 8-K · Filed: May 3, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | May 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, sec-filing, pharmaceuticals
TL;DR
Vanda Pharma inked a material deal, filing an 8-K today. Details pending.
AI Summary
On May 3, 2024, Vanda Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement. The filing also addresses modifications to the rights of security holders and includes financial statements and exhibits. Specific details of the agreement and its financial implications are not fully elaborated in the provided text.
Why It Matters
This filing indicates a significant new agreement for Vanda Pharmaceuticals, which could impact its business operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in the provided text necessitates a medium risk assessment.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- May 3, 2024 (date) — Date of Report
- 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement filed by Vanda Pharmaceuticals?
The provided text states that Vanda Pharmaceuticals Inc. entered into a material definitive agreement, but the specific details of this agreement are not elaborated upon in the excerpt.
When was this 8-K filing submitted?
The 8-K filing was submitted on May 3, 2024.
What other information is included in this 8-K filing besides the material agreement?
The filing also addresses material modifications to the rights of security holders and includes financial statements and exhibits.
What is Vanda Pharmaceuticals Inc.'s principal executive office address?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
What is Vanda Pharmaceuticals Inc.'s SIC code?
Vanda Pharmaceuticals Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 764 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-05-03 16:02:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d833979d8k.htm (8-K) — 29KB
- d833979dex41.htm (EX-4.1) — 16KB
- 0001193125-24-130668.txt ( ) — 204KB
- vnda-20240503.xsd (EX-101.SCH) — 4KB
- vnda-20240503_def.xml (EX-101.DEF) — 13KB
- vnda-20240503_lab.xml (EX-101.LAB) — 22KB
- vnda-20240503_pre.xml (EX-101.PRE) — 14KB
- d833979d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Amendment No. 1 to the Rights Agreement, dated as of May 3, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC, as rights agent. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 3, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary